Analysts Set Bicara Therapeutics Inc. (NASDAQ:BCAX) Price Target at $41.20
Bicara Therapeutics Inc. (NASDAQ:BCAX – Get Free Report) has been assigned a consensus rating of “Buy” from the eight analysts that are currently covering the firm, MarketBeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month […]
Bicara Therapeutics Inc. (NASDAQ:BCAX – Get Free Report) has been assigned a consensus rating of “Buy” from the eight analysts that are currently covering the firm, MarketBeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month […]
